A class action lawsuit has been filed against Zoetis Inc. and certain officers, alleging they made false statements about the growth and market share of key products in the Companion Animal segment. The complaint claims Zoetis failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, loss of market share for Simparica Trio to cheaper competitors, and declining sales of dermatology products Apoquel and Cytopoint. Investors who bought Zoetis securities between January 14, 2025, and May 6, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of July 27, 2026. The law firm Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency basis, seeking to recover damages for alleged securities fraud.
Zoetis Inc. is the subject of a class action lawsuit alleging it misled investors about weakening sales of key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The lawsuit claims Zoetis and its executives failed to d...
A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concern...
A class action lawsuit has been filed against Zoetis Inc. for allegedly misleading investors about the performance of its main animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The complaint claims Zoetis failed to di...
Zoetis Inc. reported flat net income of $601 million for Q1 2026 but lowered its full-year profit guidance due to weaker demand and increased price sensitivity among pet owners. Following this announcement, Zoetis's stock price fell sharply by 21.5%....
